CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Incyte reports 71% response rate for INCA33890 combination in Phase 1 colorectal cancer trial

By Public Technologies
  • Incyte presented early-stage results for cancer treatments INCB161734 and INCA33890 at the ESMO Congress 2026.
  • INCB161734 combinations showed durable responses in pancreatic cancer and antitumor activity in previously treated colorectal cancer, with manageable safety.
  • INCA33890 with standard therapies showed preliminary activity across microsatellite-stable colorectal cancer patient groups, with manageable safety.
  • Phase 3 pancreatic cancer results for INCB161734 are expected in 2028; its colorectal cancer trial should begin in the first half of 2027.
  • The ongoing Phase 3 trial of INCA33890 with chemotherapy and bevacizumab in first-line microsatellite-stable colorectal cancer expects results in 2029.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20261026987057) on October 26, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk